Jennifer J. Wilkes
Children's Hospital of Philadelphia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jennifer J. Wilkes.
Journal of Pediatric Hematology Oncology | 2015
Tina S. Ipe; Jennifer J. Wilkes; Helge Hartung; Connie M. Westhoff; Stella T. Chou; David Friedman
A 5-year-old male with sickle cell disease presented with pain, dark urine, and fatigue 10 days after a red blood cell (RBC) transfusion. Laboratory evaluation demonstrated severe anemia, blood type O+, and anti-D in the serum. Anti-D in a D+ patient led to RH genotyping, which revealed homozygosity for RHD*DAU4 that encodes partial D antigen. Anti-D in this patient whose RBCs exclusively express partial D caused a delayed hemolytic transfusion reaction after exposure to D+ RBCs. The finding of anti-D in a D+patient should be investigated by molecular methods to help distinguish an alloantibody from an autoantibody.
The Journal of Pediatrics | 2009
Jennifer J. Wilkes; Kateri H. Leckerman; Susan E. Coffin; Ron Keren; Talene A. Metjian; Richard L. Hodinka; Theoklis E. Zaoutis
Many children with influenza are treated with antibiotics. In this report, we describe the rate and indications for antibacterial use in children hospitalized with influenza. A total of 333 of 729 (46%) patients received >2 days of treatment with antibacterial medications, of whom 36% did not have an apparent indication for therapy.
American Journal of Hematology | 2017
Lena E. Winestone; Kelly D. Getz; Tamara P. Miller; Jennifer J. Wilkes; Leah Sack; Yimei Li; Yuan-Shung Huang; Alix E. Seif; Rochelle Bagatell; Brian T. Fisher; Andrew J. Epstein; Richard Aplenc
Black patients with acute myeloid leukemia (AML) experience higher mortality than White patients. We compared induction mortality, acuity of illness prior to chemotherapy, and insurance type between Black and White patients to assess whether acuity of presentation mediates the disparity. Within a retrospective cohort of 1,122 children with AML treated with two courses of standard induction chemotherapy between 2004 and 2014 in the Pediatric Health Information System (PHIS) database, the association between race (Black versus White) and inpatient mortality during induction was examined. Intensive Care Unit (ICU)‐level resource utilization during the first 72 hours following admission for initial AML chemotherapy was evaluated as a potential mediator. The total effect of race on mortality during Induction I revealed a strong association (unadjusted HR 2.75, CI: 1.18, 6.41). Black patients had a significantly higher unadjusted risk of requiring ICU‐level resources within the first 72 hours after initial presentation (17% versus 11%; RR 1.52, CI: 1.04, 2.24). Mediation analyses revealed the indirect effect of race through acuity accounted for 61% of the relative excess mortality during Induction I. Publicly insured patients experienced greater induction mortality than privately insured patients regardless of race. Black patients with AML have significantly greater risk of induction mortality and are at increased risk for requiring ICU‐level resources soon after presentation. Higher acuity amongst Black patients accounts for a substantial portion of the relative excess mortality during Induction I. Targeting factors affecting acuity of illness at presentation may lessen racial disparities in AML induction mortality.
Pediatric Blood & Cancer | 2016
Weili Sun; Etan Orgel; Jemily Malvar; Richard Sposto; Jennifer J. Wilkes; Rebecca A. Gardner; Vanessa P. Tolbert; Alison Smith; Minjun Hur; Jill A. Hoffman; Susan R. Rheingold; Michael J. Burke; Alan S. Wayne
The UK ALLR3 (R3) regimen has been adopted to treat pediatric relapsed acute lymphoblastic leukemia (ALL) by many centers in the United States and has become a preferred therapeutic backbone for testing novel agents in clinical trials. A detailed toxicity profile of this platform has not previously been reported. The toxicity and response rates for its use beyond first relapse are unknown.
Cancer | 2016
Pooja Rao; Yimei Li; Kelly D. Getz; Tamara P. Miller; Yuan-Shung Huang; Jennifer J. Wilkes; Alix E. Seif; Rochelle Bagatell; Brian T. Fisher; Clarisa R. Gracia; Richard Aplenc
Adolescents with cancer engage in sexual behaviors and are exposed to teratogenic chemotherapy. There are no data regarding pregnancy screening patterns for adolescents before chemotherapy exposure.
Cancer | 2017
Adam J. Esbenshade; Zhiguo Zhao; Catherine Aftandilian; Raya Saab; Rachel L. Wattier; Melissa Beauchemin; Tamara P. Miller; Jennifer J. Wilkes; Michael J. Kelly; Alison Fernbach; Michael Jeng; Cindy L. Schwartz; Christopher C. Dvorak; Yu Shyr; Karl G.M. Moons; Maria Luisa Sulis; Debra L. Friedman
Pediatric oncology patients are at an increased risk of invasive bacterial infection due to immunosuppression. The risk of such infection in the absence of severe neutropenia (absolute neutrophil count ≥ 500/μL) is not well established and a validated prediction model for blood stream infection (BSI) risk offers clinical usefulness.
Journal of Hospital Medicine | 2009
Jennifer J. Wilkes; Theoklis E. Zaoutis; Ron Keren; Bimal R. Desai; Kateri H. Leckerman; Richard L. Hodinka; Talene A. Metjian; Susan E. Coffin
Blood | 2014
Weili Sun; Alison Smith; Orgal Etan; Richard Sposto; Jennifer J. Wilkes; Rebecca A. Gardner; Hur Minjun; Vanessa Pineros; Emily Olson; Yijuin Tan; Susan R. Rheingold; Michael J. Burke; Alan S. Wayne
Clinical Lymphoma, Myeloma & Leukemia | 2016
Jennifer J. Wilkes; Sean Hennessy; Rui Xiao; Susan R. Rheingold; Alix E. Seif; Yuan-Shung Huang; Neika Vendetti; Yimei Li; Rochelle Bagatell; Richard Aplenc; Brian T. Fisher
Blood | 2015
Weili Sun; Jemily Malvar; Richard Sposto; Anupam Verma; Jennifer J. Wilkes; Robyn M. Dennis; Kenneth Matthew Heym; Elena Eckroth; Jeannette Vandergiesse; Paul S. Gaynon; Alan S. Wayne; James A. Whitlock